VICTORIA, SAN DIEGO, and UTRECHT, Netherlands, Jan. 20, 2020 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC
QB: IPATF) a provider of best-in-class therapeutic antibody
discovery capabilities for the global industry, and SGI-DNA, INC.,
a company dedicated to developing transformative synthetic biology
technologies and revolutionary DNA data storage solutions, today
announced that IPA is integrating SGI-DNA's benchtop automated DNA
printer to accelerate antibody discovery and manufacturing services
at its European facilities.
![ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.) ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.)](https://mma.prnewswire.com/media/1079040/ImmunoPrecise_Antibodies_Ltd__ImmunoPrecise_integrates_SGI_DNA_s.jpg)
ImmunoPrecise Antibodies will become the first CRO in
Europe to integrate the BioXp™
3200 System in its workflows as part of its vision for adopting
breakthrough technologies in the discovery and manufacturing of
antibodies. The BioXp 3200 System is the world's first benchtop
automated system that rapidly synthesizes and clones high-quality,
double-stranded DNA fragments into any vector in an overnight run.
Placing the BioXp 3200 System at IPA's Utrecht laboratories (U-Protein Express BV),
IPA will be accelerating turnaround time for generating custom DNA
for the discovery and manufacturing of antibodies and proteins.
"The BioXp 3200 System will greatly reduce our turnaround time
for cloning activities in our discovery and manufacturing projects,
positively impacting our manufacturing capacity. Moreover,
the BioXp 3200 enables additional avenues of synthetic biology,
enhancing our ability to generate, analyze and screen large numbers
of gene sequences for a variety of applications," said Dr.
Jennifer Bath, President and CEO of
ImmunoPrecise. "It fits perfectly into our continuous
implementation of new, emerging, and disruptive technologies".
Dr. Martin Hessing, General
Manager of U-Protein Express, added, "by automating rapid DNA
synthesis, we will put IPA in a competitive position, allowing
faster delivery of our antibodies."
Dan Gibson, CTO and Co-Founder of
SGI-DNA, commented, "we are pleased to partner with ImmunoPrecise
to further develop ground-breaking solutions on the BioXp platform
that will enable them to rapidly design, assemble and optimize
antibody functionality with iterative speeds not available with any
other workflow. Together, we will continue to refine
solutions that shorten the antibody design-synthesis-screening
timeline from weeks and months down to days, providing clear
advantages to their customers."
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is an international, full-service, therapeutic
antibody discovery company offering species agnostic advancements
such as the B cell Select™ progressive single-cell
interrogation technology and the DeepDisplay™ custom,
OmniAb®-based phage libraries, as well as the
Abthena™ bispecific program. IPA is focused on the next
generation of antibody discovery, to deliver the most
therapeutically relevant antibodies, in a shorter period of time,
with the highest probability of succeeding to clinical trials.
ImmunoPrecise discovery and development are conducted in
Utrecht and Oss, the Netherlands (U-Protein Express and IPA
Europe, respectively), and in Victoria,
British Columbia (IPA Canada). The Company operates globally
to offer a continuum of superior antibody services, transforming
the face of therapeutic discovery, by decreasing turnaround time
and risk, and promoting clinical success.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended October 31, 2019 which can be accessed at
www.sedar.com. The "forward-looking statements" contained
herein speak only as of the date of this press release and, unless
required by applicable law, ImmunoPrecise undertakes no obligation
to publicly update or revise such information, whether as a result
of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.